Merali S - Search Results

1

Absolute oral bioavailability of milvexian spray-dried dispersion formulation under fasted and fed conditions in healthy adult participants: An intravenous microtracer approach.

Jarugula P, Soleman S, Back H, Christopher LJ, Hawthorne D, Aronson R, Bui A, Mirzac A, Ajavon-Hartmann A, Perera V, Murthy B, Merali S. Jarugula P, et al. Among authors: merali s. Clin Transl Sci. 2024 Oct;17(10):e70058. doi: 10.1111/cts.70058. Clin Transl Sci. 2024. PMID: 39450784 Free PMC article. Clinical Trial.

2

Safety, tolerability, pharmacokinetics and pharmacodynamics of milvexian with aspirin and/or clopidogrel in healthy participants.

Perera V, Abelian G, Luettgen J, Aronson R, Li D, Wang Z, Zhang L, Lubin S, Merali S, Murthy B. Perera V, et al. Among authors: merali s. Sci Rep. 2024 Jul 18;14(1):16591. doi: 10.1038/s41598-024-67182-8. Sci Rep. 2024. PMID: 39025971 Free PMC article. Clinical Trial.

3

First-in-human study to assess the safety, pharmacokinetics, and pharmacodynamics of BMS-986141, a novel, reversible, small-molecule, PAR4 agonist in non-Japanese and Japanese healthy participants.

Merali S, Wang Z, Frost C, Meadows-Shropshire S, Hawthorne D, Yang J, Seiffert D. Merali S, et al. Platelets. 2023 Dec;34(1):2222846. doi: 10.1080/09537104.2023.2222846. Platelets. 2023. PMID: 37394920 Free article. Clinical Trial.

4

Effect of Activated Charcoal on Mavacamten Pharmacokinetics in Healthy Participants.

Merali S, Chiang M, Sychterz C, Chao L, Simmons T, Xu Y, Zhao A, Attanasio M, Murthy B, Perera V. Merali S, et al. Am J Cardiovasc Drugs. 2024 Jul;24(4):569-575. doi: 10.1007/s40256-024-00659-z. Epub 2024 Jun 26. Am J Cardiovasc Drugs. 2024. PMID: 38926266 Free PMC article. Clinical Trial.

5

First-in-Human Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of BMS-986308: A Renal Outer Medullary Potassium Channel Inhibitor.

Soleman SI, Maya J, Levesque P, Mohammad A, Christopher L, Schumacher J, Nanduri A, Sivakumar P, Kozinn M, Costet P, Wang C, Richter J, Hawthorne D, Bui A, Rao VS, Dickerson D, Testani J, Ramírez-Valle F, Baribaud F, Murthy B, Merali S. Soleman SI, et al. Among authors: merali s. Clin Pharmacol Ther. 2024 Dec;116(6):1627-1634. doi: 10.1002/cpt.3430. Epub 2024 Sep 2. Clin Pharmacol Ther. 2024. PMID: 39219444 Clinical Trial.

6

Evaluation of safety, pharmacokinetics, and pharmacodynamics of apixaban in pediatric subjects at risk of venous or arterial thrombotic disorder.

Merali SJ, Byon W, Patel YT, Elsrougy A, Marchisin D, Perera V, Chen W, He B, Murthy B. Merali SJ, et al. CPT Pharmacometrics Syst Pharmacol. 2023 Apr;12(4):500-512. doi: 10.1002/psp4.12935. Epub 2023 Mar 5. CPT Pharmacometrics Syst Pharmacol. 2023. PMID: 36861188 Free PMC article. Clinical Trial.

7

Drug-Drug Interaction Potential of Mavacamten with Oral Contraceptives: Results from a Clinical Pharmacokinetic Study and a Physiologically Based Pharmacokinetic Model.

Chiang M, Sychterz C, Gaohua L, Perera V, Gretler DD, Florea V, Merali S. Chiang M, et al. Among authors: merali s. J Clin Pharmacol. 2023 Nov;63(11):1275-1282. doi: 10.1002/jcph.2298. Epub 2023 Jul 26. J Clin Pharmacol. 2023. PMID: 37376778

8

Characterization of mavacamten pharmacokinetics in patients with hypertrophic cardiomyopathy to inform dose titration.

Chang P, Perera V, Salinger DH, Merali S, Thanneer N, Back H, Seroogy JD, Gretler DD, Sehnert AJ, Palmisano M, Roy A. Chang P, et al. Among authors: merali s. CPT Pharmacometrics Syst Pharmacol. 2024 Sep;13(9):1462-1475. doi: 10.1002/psp4.13197. Epub 2024 Aug 13. CPT Pharmacometrics Syst Pharmacol. 2024. PMID: 39136278 Free PMC article.

9

Physiologically Based Pharmacokinetic Modeling and Simulation of Mavacamten Exposure with Drug-Drug Interactions from CYP Inducers and Inhibitors by CYP2C19 Phenotype.

Chiang M, Sychterz C, Perera V, Merali S, Palmisano M, Templeton IE, Gaohua L. Chiang M, et al. Among authors: merali s. Clin Pharmacol Ther. 2023 Oct;114(4):922-932. doi: 10.1002/cpt.3005. Epub 2023 Aug 6. Clin Pharmacol Ther. 2023. PMID: 37467157

10

Recommendation of mavacamten posology by model-based analyses in adults with obstructive hypertrophic cardiomyopathy.

Merali S, Salinger DH, Palmisano M, Sehnert AJ, Thanneer N, Back H, Seroogy JD, Gretler DD, Roy A, Perera V. Merali S, et al. CPT Pharmacometrics Syst Pharmacol. 2024 Sep;13(9):1448-1461. doi: 10.1002/psp4.13138. Epub 2024 May 2. CPT Pharmacometrics Syst Pharmacol. 2024. PMID: 38695527 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

132 results

Search Page

Filters